Osaic Holdings
ZVRA icon

Osaic Holdings’s Zevra Therapeutics ZVRA Stock Holding History

Osaic Holdings’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.13M Buy
78,928
+72,551
+1,138% +$807K ﹤0.01% 2885
2026
Q1 		$59.4K Buy
6,377
+5,143
+417% +$46.4K ﹤0.01% 5075
2025
Q4 		$11.1K Sell
1,234
-25
-2% -$236 ﹤0.01% 6285
2025
Q3 		$11.5K Sell
1,259
-875
-41% -$8.78K ﹤0.01% 6278
2025
Q2 		$18.8K Sell
2,134
-200
-9% -$1.62K ﹤0.01% 5764
2025
Q1 		$17.5K Buy
2,334
+410
+21% +$3.26K ﹤0.01% 5449
2024
Q4 		$16K Buy
1,924
+175
+10% +$1.49K ﹤0.01% 5500
2024
Q3 		$12.1K Buy
1,749
+100
+6% +$679 ﹤0.01% 5696
2024
Q2 		$8.08K Sell
1,649
-550
-25% -$2.61K ﹤0.01% 5917
2024
Q1 		$12.8K Sell
2,199
-2,500
-53% -$15.4K ﹤0.01% 5619
2023
Q4 		$30.8K Sell
4,699
-463
-9% -$2.17K ﹤0.01% 5227
2023
Q3 		$24.9K Buy
5,162
+425
+9% +$2.12K ﹤0.01% 5427
2023
Q2 		$24.2K Buy
4,737
+600
+15% +$3.23K ﹤0.01% 5439
2023
Q1 		$22.8K Buy
4,137
+600
+17% +$3.17K ﹤0.01% 5504
2022
Q4 		$16K Buy
3,537
+2,557
+261% +$13K ﹤0.01% 5721
2022
Q3 		$6K Hold
980
– – ﹤0.01% 6314
2022
Q2 		$4K Sell
980
-3,555
-78% -$16.2K ﹤0.01% 6643
2022
Q1 		$24K Hold
4,535
– – ﹤0.01% 5591
2021
Q4 		$40K Hold
4,535
– – ﹤0.01% 5312
2021
Q3 		$42K Buy
4,535
+3,543
+357% +$35.7K ﹤0.01% 5238
2021
Q2 		$13K Sell
992
-515
-34% -$5.54K ﹤0.01% 5920
2021
Q1 		$13K Buy
+1,507
New +$13.2K ﹤0.01% 5750
2020
Q2 		– Sell
-911
Closed -$3K – 6366
2020
Q1 		$3K Buy
+911
New +$5.04K ﹤0.01% 5589

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Osaic Holdings's ZVRA Position: Q2 2026 in Review

Osaic Holdings increased its Zevra Therapeutics (ZVRA) stake by 1,138% in Q2 2026, buying an estimated $807K and bringing the position to 78,928 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #2885.

Osaic Holdings first reported a position in ZVRA in Q1 2020 and has held it in 23 quarters since. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Osaic Holdings held 78,928 shares of Zevra Therapeutics worth $1.13M as of Q2 2026.
  • Osaic Holdings bought 72,551 Zevra Therapeutics shares in Q2 2026, an estimated $807K.
  • Zevra Therapeutics made up ﹤0.01% of Osaic Holdings's portfolio in Q2 2026, its #2885 holding.
  • Osaic Holdings first reported a position in Zevra Therapeutics in Q1 2020 and has held it in 23 quarters since.
  • 157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.